Brief: Finch Therapeutics Further Strengthens Patent Portfolio With Two New U.S. Patents Granted For Fin-211, An Investigational Microbiome Therapeutic In Development For Autism Spectrum Disorder
06/01/2022 12:18
Jan 6 (Reuters) - Finch Therapeutics Group Inc FNCH.O :
* FINCH THERAPEUTICS FURTHER STRENGTHENS PATENT PORTFOLIO
WITH TWO
NEW U.S. PATENTS GRANTED FOR FIN-211, AN INVESTIGATIONAL
MICROBIOME THERAPEUTIC IN DEVELOPMENT FOR AUTISM SPECTRUM
DISORDER
* FINCH THERAPEUTICS GROUP INC - FIRST AND SECOND PATENTS
HAVE
EXPIRATION DATES IN 2036 AND 2031, RESPECTIVELY
Source text for Eikon: ID:nGNX37Kg9C
Further company coverage: FNCH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Finch Therapeutics
See all newsFinch wins US jury trial against Ferring over fecal-transplant patents
Brief: Finch Therapeutics Group Received A Notice From Nasdaq Acknowledging Fact That Co Does Not Meet Requirements Of Rules On April 2
Brief: Finch Therapeutics Got Letter From Nasdaq That Co Has Regained Compliance With Nasdaq’s Listing Rule 5450(A)(1)
U.S. STOCKS ON THE MOVE-Gold miners, ImmunoGen, Oracle
U.S. STOCKS ON THE MOVE-Teekay, gold miners, Oil-Dri Corp